Aurobindo Pharma Ltd v. Azurity Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Aurobindo Pharma Ltd. (India)
  • Defendant: Azurity Pharmaceuticals Inc. (Delaware); Azurity Pharmaceuticals Ireland Limited (Ireland)
  • Plaintiff's Counsel: Stamoulis & Weinblatt LLC
• Case Identification: 1:26-cv-00265, D. Del., 03/12/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because Defendant Azurity Pharmaceuticals Inc. is a Delaware corporation that conducts business in the district, and the district is a destination for its pharmaceutical products.
• Core Dispute: Plaintiff, a generic drug manufacturer, seeks a declaratory judgment that its proposed generic version of Gabapentin Enacarbil extended-release tablets does not infringe, and/or that the patent is invalid, for U.S. Patent No. 8,795,725, which is listed in the FDA's Orange Book for the corresponding branded drug.
• Technical Context: The technology concerns sustained-release oral pharmaceutical formulations of a prodrug for gabapentin, designed to control the drug's absorption and maintain its therapeutic effect over an extended period.
• Key Procedural History: This is a declaratory judgment action filed under the Hatch-Waxman Act. The plaintiff, Aurobindo, filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting non-infringement of the defendant's patent. After receiving notice, the defendant patent holder, Azurity, did not initiate an infringement suit within the statutory 45-day window, prompting Aurobindo to file this action to resolve the legal uncertainty regarding its freedom to operate.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,795,725 - "GABA analog prodrug sustained release oral dosage forms"

• Patent Identification: U.S. Patent No. 8,795,725, "GABA analog prodrug sustained release oral dosage forms," issued August 5, 2014 (hereinafter "'725 Patent").

The Invention Explained

• Problem Addressed: The patent's background section explains that a specific prodrug of gabapentin, 1-{[(a-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, possesses high bioavailability, making it a valuable therapeutic agent for conditions like epilepsy, neuropathic pain, and restless legs syndrome '725 Patent, col. 1:17-40 The technical challenge is to create a dosage form that delivers this prodrug in a sustained-release manner, which can provide prolonged therapeutic effects and potentially improve patient compliance through less frequent dosing.
• The Patented Solution: The invention is a solid oral tablet formulated to release the gabapentin prodrug over an extended period '725 Patent, abstract The solution involves combining the active prodrug with specific excipients, notably a "release rate-modifying polymer" such as a glyceryl ester, to control the rate at which the drug dissolves after ingestion '725 Patent, col. 2:19-29 This formulation is designed to produce a specific, prolonged concentration curve of gabapentin in a patient's blood plasma, as depicted in the patent's pharmacokinetic profile graphs '725 Patent, FIG. 1 '725 Patent, col. 2:36-46
• Technical Importance: A successful sustained-release formulation can offer significant clinical advantages over immediate-release versions, including more stable drug concentrations in the blood, a reduced dosing frequency (e.g., once or twice daily), and potentially fewer side effects '725 Patent, col. 11:5-18

Key Claims at a Glance

• The complaint seeks a declaration of non-infringement of "any valid or enforceable claim" of the '725 patent Compl. ¶32 Independent claim 1 is representative of the patent's composition-of-matter claims defined by functional pharmacokinetic (PK) outcomes.
• Independent Claim 1: The essential elements are:
  • A sustained release oral tablet comprising:
  • (a) 40 wt% to 65 wt% of the gabapentin prodrug;
  • (b) 1 wt% to 30 wt% of glyceryl behenate; and
  • (c) 30 wt% to 50 wt% of dibasic calcium phosphate.
  • The tablet, when administered at a specific dose, provides a gabapentin plasma concentration profile defined by specific ranges for its maximum concentration (Cmax), time to maximum concentration (Tmax), and area under the curve (AUC) in either fasted or fed human patients.
• The complaint implicitly reserves the right to challenge any claims of the '725 patent, including dependent claims.

III. The Accused Instrumentality

Product Identification

The product at issue is "Aurobindo's Proposed ANDA Gabapentin Enacarbil Extended-release Tablets, 300 mg and 600 mg," as described in Abbreviated New Drug Application (ANDA) 220257 Compl. ¶23

Functionality and Market Context

• The complaint describes the product as a "generic form" of the branded drug HORIZANT® Gabapentin Enacarbil Extended-release Tablets Compl. ¶1 As a generic, its intended function is to be therapeutically equivalent to the branded product, providing a sustained release of gabapentin enacarbil.
• The complaint does not provide specific technical details about the formulation, excipients, or dissolution profile of Aurobindo's proposed product.
• The product is positioned to be a lower-cost generic alternative to the branded HORIZANT® drug upon receiving FDA approval Compl. ¶1

IV. Analysis of Infringement Allegations

The complaint is a declaratory judgment action for non-infringement and therefore does not contain affirmative infringement allegations or a claim chart. The central allegation is that Aurobindo's proposed generic product "would not infringe any valid or enforceable claim of the '725 patent" Compl. ¶32 The infringement analysis will thus focus on whether Aurobindo's product, as defined in its ANDA, falls within the scope of the '725 patent's claims.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Scope Questions: A primary issue for the court will be whether the specific formulation of Aurobindo's product falls within the claimed weight percentage ranges for the three key ingredients recited in Claim 1: the prodrug, glyceryl behenate, and dibasic calcium phosphate. The dispute may center on whether Aurobindo has successfully "designed around" these specific compositional requirements by using different excipients or different quantities of the same excipients.
  • Technical Questions: For the functional limitations of Claim 1, a central question will be one of bioequivalence versus infringement. The court will need to determine if Aurobindo's product, even if deemed bioequivalent to HORIZANT® for FDA regulatory purposes, necessarily produces the specific Cmax, Tmax, and AUC pharmacokinetic profile recited in the claim when tested under the claim's precise conditions. The parties may dispute whether the PK data from Aurobindo's ANDA studies meets the claimed profile parameters.

V. Key Claim Terms for Construction

• The Term: "glyceryl behenate" (from Claim 1)

  • Context and Importance: This term recites the specific release rate-modifying polymer in Claim 1. The construction of this term is critical because if Aurobindo's formulation uses a different but functionally similar waxy excipient, the infringement analysis may depend entirely on whether that alternative falls within the scope of this term.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification introduces glyceryl behenate as an example within a broader class of "glyceryl esters," which are themselves a type of "release rate-modifying polymer" '725 Patent, col. 7:16-20 A party could argue the term should be understood in this broader context.
    • Evidence for a Narrower Interpretation: Claim 1 recites the specific compound "glyceryl behenate," not the broader class of "glyceryl esters." The patent specification also lists it alongside other distinct esters like "glyceryl monostearate" and "glyceryl palmitostearate," suggesting the patentee intended to distinguish between them '725 Patent, col. 7:17-18

• The Term: "a gabapentin plasma concentration profile characterized by..." (from Claim 1)

  • Context and Importance: This functional language defines the patented tablet by the in-vivo result it produces. Infringement requires showing that the accused product meets these specific pharmacokinetic parameters. The interpretation of how strictly these numerical ranges must be met will be dispositive.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party might argue that "characterized by" does not require that every data point from every subject fall strictly within the recited ranges, but that the overall profile generally conforms to them, accounting for normal biological and experimental variability. The patent's own figures show PK profiles with standard deviation bars, acknowledging such variability '725 Patent, FIG. 1 '725 Patent, FIG. 2
    • Evidence for a Narrower Interpretation: A party could argue that the claim requires the mean PK parameters from a properly conducted clinical study to fall squarely within the recited numerical boundaries. The claims provide precise numerical endpoints (e.g., Cmax "ranging from about 3 µg/mL to about 6 µg/mL"), which suggests these are intended as firm limitations on the claim scope '725 Patent, col. 19:13-16

VI. Other Allegations

The complaint does not provide sufficient detail for analysis of indirect or willful infringement, as it is a declaratory judgment action for non-infringement brought by the accused infringer.

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of compositional scope: has Aurobindo formulated its proposed generic tablet with excipients and/or weight percentages that fall outside the specific ranges claimed for the active prodrug, glyceryl behenate, and dibasic calcium phosphate in the '725 patent's independent claims?
• A key evidentiary question will be one of functional performance: does the pharmacokinetic data from Aurobindo's ANDA demonstrate that its product, when administered as specified in Claim 1, produces a gabapentin plasma concentration profile that falls within the patent's precise Cmax, Tmax, and AUC ranges, or does the product achieve FDA-required bioequivalence through a different, non-infringing PK profile?